マルチモーダルイメージングの米国市場の評価：技術別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

米国のマルチモーダルイメージングの市場規模は、2023年の16億5,000万米ドルから2031年に25億3,000万米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで5.50％の成長が見込まれます。先進イメージングソリューションの採用拡大、有利な償還シナリオ、新製品の承認など、複数の重要な要因により、米国のマルチモーダルイメージング産業は速いペースで成長しています。

PET/CT、PET/MRI、SPECT/CTなどの診断法を組み合わせたマルチモーダルイメージングは、包括的な解剖学的、機能的、分子的見識を提供し、心臓、神経、腫瘍などの分野で治療計画や診断精度を向上させる可能性があります。データ処理の高速化、センサーの高解像度化、AIを活用した画像処理など、技術の向上がこれらのシステムの有効性を大きく高めています。臨床研究や個別化医療における利用の拡大も、市場拡大を促進しています。先進のイメージング技術の採用は、医学研究やインフラへの多額の投資、支援的な法律枠組みによってさらに後押しされています。悪性腫瘍や慢性疾患の罹患率の増加は、正確な診断機器へのニーズをさらに高めています。

さらに、これらの診断ツールは、よりコンパクトな可動式システムの開発により、孤立した地域や十分なサービスを受けられない地域でも、より広く利用できるようになっています。たとえば2023年5月、FDAが12歳以上の患者への使用を承認したことを受けて、Cincinnati Children's Hospital Medical Centreは、キセノンMRI（XENOVIEW）、すなわち肺の換気を安全かつ詳細に表示できる新しいキセノン（Xe）混合ガスを使用して患者を診断した米国初の病院となっています。

当レポートでは、米国のマルチモーダルイメージング市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 米国のマルチモーダルイメージング市場の見通し（2017年～2031年）

• 市場規模の分析と予測
  • 金額
  • 数量
• 市場シェアの分析と予測
  • 技術別
  • 用途別
  • エンドユーザー別
  • 地域別
  • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
• 市場マップ分析（2023年）
  • 技術別
  • 用途別
  • エンドユーザー別
  • 地域別

第5章 需給分析

第6章 輸入と輸出の分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場促進要因
• 市場の課題

第12章 市場の動向と発展

第13章 規制枠組みとイノベーション

• 規制当局の承認

第14章 特許情勢

第15章 ケーススタディ

第16章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 上位10社の市場企業の主要企業の情勢
  • GE Healthcare Technologies Inc.
  • Canon Medical Systems Corporation
  • Koninklijke Philips N.V.
  • Siemens Healthineers AG
  • Carl Zeiss AG
  • Mediso Ltd.
  • Neusoft Medical Systems Co. Ltd.
  • Bruker Corporation
  • Spectrum Dynamics Medical Group Limited
  • MILabs B.V.

第17章 戦略的推奨

第18章 当社について、免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Multimodal Imaging Market, By Value, In USD Billion, 2017-2031F
• Figure 2. United States Multimodal Imaging Market, By Volume, In Million Units, 2017-2031F
• Figure 3. United States Multimodal Imaging Market Share (%), By Technology, 2017-2031F
• Figure 4. United States Multimodal Imaging Market Share (%), By Application, 2017-2031F
• Figure 5. United States Multimodal Imaging Market Share (%), By End-user, 2017-2031F
• Figure 6. United States Multimodal Imaging Market Share (%), By Region, 2017-2031F
• Figure 7. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 8. By Application Size Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 9. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 10. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

United States multimodal imaging market is projected to witness a CAGR of 5.50% during the forecast period 2024-2031, growing from USD 1.65 billion in 2023 to USD 2.53 billion in 2031. Due to several important factors, such as the growing adoption of advanced imaging solutions, favorable reimbursement scenarios, and new product approvals, the multimodal imaging industry in the United States is growing at a faster pace.

The combination of diagnostic methods such as PET/CT, PET/MRI, and SPECT/CT, multimodal imaging provides comprehensive anatomical, functional, and molecular insights that have the potential to improve treatment planning and diagnostic accuracy in fields like cardiology, neurology, and oncology. Improvements in technology, such as faster data processing, higher resolution sensors, and AI-driven imagery, are greatly increasing the effectiveness of these systems. Growing applications in clinical research and personalized medicine also fuel market expansion. The adoption of advanced imaging technologies is further aided by significant investments in healthcare research and infrastructure as well as by supportive legislative frameworks. The rising incidence of malignancies and chronic illnesses further fuels the need for accurate diagnostic instruments.

Furthermore, these diagnostic tools are now more widely available, even in isolated or underserved areas, due to the development of portable systems that are much more compact. For instance, in May 2023, following its FDA approval for use in patients of 12 years age and older, Cincinnati Children's Hospital Medical Centre became the first hospital in the United States to diagnose a patient using xenon MRI, or XENOVIEW, a novel xenon (Xe) gas blend that allows a safe and detailed view of lung ventilation.

Market Growth Due to Technological Advancements

Technological developments are driving the multimodal imaging industry in the United States. Artificial intelligence (AI) and machine learning (ML) algorithms are examples of modern advances that improve picture quality, processing, and interpretation, leading to more precise and effective imaging systems. Hybrid PET/MRI and PET/CT are examples of advanced imaging techniques that combine multiple modalities to deliver rich anatomical and functional information in a single session, providing maximum possible insights. More accurate diagnoses and better patient results are also a result of advancements in imaging hardware, such as faster data processing speeds and higher-resolution sensors. The amalgamation of cloud computing with telemedicine additionally expedites distant consultations and data exchange, hence expanding the reach and practicality of multimodal imaging.

Furthermore, growing investments in research and development drive continuous innovation, creating new applications and expanding market potential. Collectively, these technological advancements enhance diagnostic capabilities and streamline workflows, fueling the expansion of the multimodal imaging market in the United States. For instance, in November 2022, Spectrum Dynamics Medical Group Limited unveiled VERITON-CT 400 Series of SPECT/CT platform under their digital nuclear medicine imaging portfolio. The systems employ solid-state detector technology, allowing imaging applications for the entire body, brain, heart, and other parts of the body.

Rising Application of Multimodal Imaging Boosts the Market Growth

The United States multimodal imaging market is expanding at a substantial rate because of the growing use of multimodal imaging equipment. Multimodal imaging combines anatomical, functional, and molecular data to produce comprehensive diagnostic information by integrating many imaging techniques, including PET/CT, PET/MRI, and SPECT/CT. This integration improves treatment planning and diagnostic accuracy, especially in oncology, neurology, and cardiology, where precise imaging is essential. Multimodal imaging has a significant market potential due to its increasing application in clinical research and personalized medicine, which allows more precise disease monitoring and individualized treatment plans. Advances in imaging technology have also increased the affordability and accessibility of these systems, leading to a rise in their use in clinical and research contexts. As healthcare providers seek to improve patient outcomes and streamline diagnostics, the demand for sophisticated multimodal imaging solutions continues to rise.

Consequently, the expanding range of applications and benefits drive market growth, reflecting a broader trend towards integrated and precise diagnostic imaging. For instance, the FDA's approval of Siemens Healthineers AG's Biograph Vision.X PET/CT scanner, received in November 2023, serves as a prime example of the growing use of multimodal imaging. The United States multimodal imaging market is expanding due to the increased need for integrated imaging solutions, which is seen in this advanced system that combines PET and CT for enhanced cancer diagnosis.

Promising Growth of PET/MRI Segment in the United States Multimodal Imaging Market

The United States multimodal imaging market is growing at a substantial rate due to the dominance of the PET/MRI segment. PET/MRI combines high-resolution anatomical imaging of magnetic resonance imaging (MRI) with sophisticated functional imaging capabilities of positron emission tomography (PET). This combination offers a thorough research and study of both structural and metabolic problems, improving therapy planning and diagnostic accuracy, particularly in the fields of neurology and oncology. The PET/MRI technology is gaining traction among healthcare professionals due to its capability to produce detailed images with less radiation exposure when compared to traditional PET/CT scans. Adoption of PET/MRI systems is also fuelled by the quick advances in technology, which include faster data capture and better image resolution.

As medical professionals and researchers increasingly recognize the value of PET/MRI in delivering superior diagnostic insights and improving patient outcomes, the segment's prominence grows, contributing to the overall expansion of the multimodal imaging market in the United States. For instance, the FDA granted 510(k) clearance for FUJIFILM Healthcare Americas Corporation's new 1.5 Tesla magnetic resonance imaging (MRI) system, the ECHELON Synergy, in August 2023.

Neurology Segment Dominates Multimodal Imaging Market

Multimodal imaging technology is capable of obtaining fine-grained images of nervous systems, thus can be used to diagnose a number of neurological conditions, ranging from stroke, traumatic brain injury, brain and spinal cord tumors, inflammation, infection, vascular abnormalities, brain damage connected to epilepsy to abnormally formed brain regions, and other neurodegenerative illnesses. Due to the growing use of multimodal imaging in the diagnosis of neurological diseases and the development of sophisticated equipment for neurology, the neurology segment of the market is anticipated to rise significantly. Additionally, it is anticipated that the rise in neurological conditions like dementia and Alzheimer's disease will increase demand for MRI machines in the United States, which will probably support the market's expansion throughout the projection period. For example, the Alzheimer's Disease Facts and Figures 2023 study estimates that 6.7 million Americans 65 years of age and older will receive an Alzheimer's dementia diagnosis in 2023. Furthermore, it is anticipated that by 2050, there would be 12.7 million of them living in the United States.

Future Market Scenario (2024-2031F)

The main factors contributing to the anticipated growth of the multimodal imaging systems market are the rising numbers of chronic diseases, increasing population and awareness, and thus, the rising need to conduct diagnostic tests. However, the growing need for precision medicine to maintain a healthy population is also going to fuel market growth in the future. Given that technology is advancing, cutting-edge technology in the area is expected. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. Government policies and policies made by welfare bodies are also greatly fueling the market expansion.

For instance, in October 2023, Koninklijke Philips N.V. (Philips) announced its collaboration with Quibim, S.L. (Quibim) to introduce advanced AI-driven imaging software aimed at prostate cancer detection. By combining Philips' innovative AI-enhanced MR imaging software with Quibim's AI-powered image analysis software, healthcare providers can expedite and simplify prostate cancer diagnosis and care.

Key Players Landscape and Outlook

Companies operating in the market are complying with new strategic initiatives regarding the launches of newly developed multimodal imaging techniques, to help researchers and to strengthen their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments and partnerships are a few ways through which they are trying to achieve the same.

For example, in June 2024, Positron Corporation, a manufacturer of advanced molecular imaging medical device has entered a business cooperation agreement with Shenyang Intelligent Neuclear Medical Technology Co. Through this cooperation agreement, Positron Corporation has entered US market and expanded sale of its FDA approved NeuSight PET-CT 64 slice scanner.

Moreover, in July 2022, Canon Medical Systems USA Inc. has acquired NXC Imaging, Inc., a diagnostic imaging equipment distributor and service. This acquisition has helped Canon to expand its penetration of sales and services in the Upper Midwest region.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. United States Multimodal Imaging Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Technology
    • 4.2.1.1. PET/CT Systems
    • 4.2.1.2. SPECT/CT Systems
    • 4.2.1.3. PET/MR Systems
    • 4.2.1.4. OCT/FM Systems
    • 4.2.1.5. Others
  • 4.2.2. By Application
    • 4.2.2.1. Cardiology
    • 4.2.2.2. Oncology
    • 4.2.2.3. Neurology
    • 4.2.2.4. Orthopedic
    • 4.2.2.5. Others
  • 4.2.3. By End-user
    • 4.2.3.1. Hospitals
    • 4.2.3.2. Diagnostic and Imaging Centers
    • 4.2.3.3. Research Institutes
    • 4.2.3.4. Others
  • 4.2.4. By Region
    • 4.2.4.1. Northeast
    • 4.2.4.2. Midwest
    • 4.2.4.3. West
    • 4.2.4.4. South
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Technology
  • 4.3.2. By Application
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players*
  • 16.3.1. GE Healthcare Technologies Inc.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Canon Medical Systems Corporation
  • 16.3.3. Koninklijke Philips N.V.
  • 16.3.4. Siemens Healthineers AG
  • 16.3.5. Carl Zeiss AG
  • 16.3.6. Mediso Ltd.
  • 16.3.7. Neusoft Medical Systems Co. Ltd.
  • 16.3.8. Bruker Corporation
  • 16.3.9. Spectrum Dynamics Medical Group Limited
  • 16.3.10. MILabs B.V.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer